IL6 and COVID-19: Its inhibition leads to the reduction of inflammatory cytokines and chemokines, such as TNFα, IL-1, IL-6 and MCP-1, which are thought to be primarily involved in exuberant systemic inflammatory responses in COVID-19 patients [51].